BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kc R, Thapa B, Ubeda A, Jiang X, Uludağ H. BCR-Abl Silencing by siRNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy. Stem Cells Dev 2019;28:734-44. [PMID: 30585758 DOI: 10.1089/scd.2018.0196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Talebpour A, Alipour R, Sajjadi SM, Osmani F, Sarab GA. In Vitro Cytotoxicity of Ferula asafoetida Gum Extract on Human Chronic Myelogenous Leukemia K562 Cells. Pharm Chem J. [DOI: 10.1007/s11094-022-02627-w] [Reference Citation Analysis]
2 Berger M, Lechanteur A, Evrard B, Piel G. Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? Int J Pharm 2021;605:120851. [PMID: 34217823 DOI: 10.1016/j.ijpharm.2021.120851] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
3 Mohseni M, Kucharski C, K C RB, Nasrullah M, Jiang X, Uludağ H, Brandwein J. Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL). PLoS One 2021;16:e0251719. [PMID: 34157051 DOI: 10.1371/journal.pone.0251719] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ansari AS, K C R, Jiang X, Uludaǧ H. Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy. J Biomed Mater Res A 2021. [PMID: 33964112 DOI: 10.1002/jbm.a.37214] [Reference Citation Analysis]
5 Misiak P, Markiewicz KH, Szymczuk D, Wilczewska AZ. Polymeric Drug Delivery Systems Bearing Cholesterol Moieties: A Review. Polymers (Basel) 2020;12:E2620. [PMID: 33172152 DOI: 10.3390/polym12112620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Biswas A, Rajesh Y, Mitra P, Mandal M. ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors. Biochim Biophys Acta Rev Cancer 2020;1874:188389. [PMID: 32659251 DOI: 10.1016/j.bbcan.2020.188389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Remant KC, Thapa B, Valencia-Serna J, Domun SS, Dimitroff C, Jiang X, Uludağ H. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy. J Biomed Mater Res A 2020;108:565-80. [PMID: 31714657 DOI: 10.1002/jbm.a.36837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
8 Xin P, Xu W, Zhu X, Li C, Zheng Y, Zheng T, Cheng W, Peng Q. Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia. Cancer Manag Res 2019;11:7933-51. [PMID: 31686909 DOI: 10.2147/CMAR.S204472] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Valencia-Serna J, Kucharski C, Chen M, Kc R, Jiang X, Brandwein J, Uludağ H. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers. J Control Release 2019;310:141-54. [PMID: 31430499 DOI: 10.1016/j.jconrel.2019.08.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]